Spots Global Cancer Trial Database for borderline resectable
Every month we try and update this database with for borderline resectable cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | NCT02749136 | Pancreatic Aden... | Preoperative mo... | 19 Years - | Asan Medical Center | |
| Project Survival-Prospective Biomarker Discovery | NCT02781012 | Pancreatic Neop... Pancreatic Canc... Pancreatitis Pancreatic Aden... Metastatic Panc... | 18 Years - | Pancreatic Cancer Research Team | ||
| Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | NCT01560949 | Pancreatic Canc... | Oxaliplatin Irinotecan 5-FU Gemcitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer | NCT03199144 | Pancreatic Neop... | Chemotherapy Stereotactic ra... Surgery | 18 Years - | Centre Francois Baclesse, Luxembourg | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | NCT02305186 | Pancreatic Canc... | Pembrolizumab Neoadjuvant Che... | 18 Years - | University of Virginia | |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | NCT02598349 | Pancreatic Canc... | Proton Radiatio... Capecitabine Surgical resect... | 18 Years - | Proton Collaborative Group | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | NCT02598349 | Pancreatic Canc... | Proton Radiatio... Capecitabine Surgical resect... | 18 Years - | Proton Collaborative Group | |
| SBRT Pre-operatively for Pancreatic Cancer | NCT02308722 | Pancreatic Neop... | 5-fraction ster... | 16 Years - | University of Oxford | |
| Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | NCT02305186 | Pancreatic Canc... | Pembrolizumab Neoadjuvant Che... | 18 Years - | University of Virginia | |
| FOLFIRINOX + RT for Pancreatic Cancer | NCT01591733 | Pancreatic Canc... | FOLFIRINOX Capecitabine Short Course Ra... Surgery | 18 Years - | Massachusetts General Hospital | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| FOLFIRINOX + RT for Pancreatic Cancer | NCT01591733 | Pancreatic Canc... | FOLFIRINOX Capecitabine Short Course Ra... Surgery | 18 Years - | Massachusetts General Hospital | |
| Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer | NCT03199144 | Pancreatic Neop... | Chemotherapy Stereotactic ra... Surgery | 18 Years - | Centre Francois Baclesse, Luxembourg | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) | NCT04793932 | Pancreas Ductal... | PAXG mFOLFIRINOX short-course ch... long-course che... | 18 Years - 75 Years | Associazione Italiana per lo Studio del Pancreas | |
| Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | NCT03299946 | Locally Advance... | Cabozantinib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | NCT02843945 | Pancreatic Canc... | Directional Bra... | 18 Years - | CivaTech Oncology | |
| A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program | NCT02218801 | Liver Metastasi... Colorectal Carc... | Evaluation of t... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer | NCT01676259 | Pancreatic Duct... Pancreatic Canc... | siG12D-LODER Gemcitabine+nab... Folfirinox | 18 Years - | Silenseed Ltd | |
| Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas | NCT01560949 | Pancreatic Canc... | Oxaliplatin Irinotecan 5-FU Gemcitabine Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas | NCT03153410 | Pancreatic Canc... | Cyclophosphamid... GVAX Pembrolizumab IMC-CS4 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | NCT02749136 | Pancreatic Aden... | Preoperative mo... | 19 Years - | Asan Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
